Successful treatment with sorafenib in patients with advanced hepatocellular carcinoma: clinical case
Multi-kinase inhibitor sorafenib is the only one drug which increases life time in patients with advanced hepatocellular carcinoma (HCC). Results from the SHARP trial showed that median progression-free survival was less than 5 months. However, it is possible to achieve strong treatment effect for s...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2014-06-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/26969 |